Epeius Pharma
Delivery of Therapeutic Proteins into the Central Nervous System
Company Overview
Snapshot
Founded in February 2019 by Prof. Oded Rechavi and Shahar Bracha, Epeius Pharma operates with 1–10 employees. The company has raised $3.5M across one funding round from two investors. In January 2020, FutuRx, in collaboration with Ramot at Tel-Aviv University and Glasgow University, launched Epeius Pharma to advance treatments for complex neurological diseases.
Business overview
Epeius Pharma is a cell and gene therapy company focused on developing biological vehicles for the precise delivery of therapeutic proteins into the central nervous system. Its platform aims to provide an effective and scalable strategy for disease modification in neurodevelopmental and neurological pathologies that could benefit from direct neuron protein replacement treatments, with an initial focus on Rett syndrome. The company operates within the Health Tech & Life Sciences sector, specifically targeting Pharmaceuticals within the Pharma & Medical Biotechnology and Drug Delivery categories.
Strategic signal
In January 2020, Epeius Pharma was launched by FutuRx, Ramot at Tel-Aviv University, and Glasgow University to develop treatments for complex neurological diseases. This collaboration signals strong institutional validation and a strategic commitment to addressing significant unmet medical needs in neurodevelopmental and neurological pathologies, leveraging academic research into a commercial venture.
Log in to access full profile ›Company Intelligence Q&A
- What is Epeius Pharma's primary focus?
- Epeius Pharma is a cell and gene therapy company developing biological vehicles for the delivery of therapeutic proteins into the central nervous system, targeting neurodevelopmental and neurological pathologies.
- When was Epeius Pharma founded and by whom?
- Epeius Pharma was founded in February 2019 by Prof. Oded Rechavi and Shahar Bracha, based on joint research efforts from Tel Aviv University and Glasgow University.
- Which organizations were involved in the launch of Epeius Pharma?
- In January 2020, FutuRx, together with Ramot at Tel-Aviv University and Glasgow University, launched Epeius Pharma to develop treatments for complex neurological diseases.
- What is Epeius Pharma's initial target indication?
- Epeius Pharma's first target indication for its therapeutic protein delivery platform is Rett syndrome.
- What is the total capital raised by Epeius Pharma?
- Epeius Pharma has raised a total of $3.5M across one funding round.